Clinical trials: Regorafenib
Pharmacokinetics
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.
- Trial name
- NCT01318265
- Testing
- Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Dietary Fats, Pharmacokinetics
The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
- Trial name
- NCT01002378
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Gastrointestinal Stromal Tumors, Metastasis
Salvage Surgery for Patients With Metastatic GIST With Rego
Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-line sunitinib.
- Conditions
- Gastrointestinal Stromal Tumors, Metastasis, Disease Progression
- Trial name
- NCT04343456
- Testing
- Salvage surgery with massive debulking
- Where
- Taiwan
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Neoplasms
Effect of Neomycin on the Pharmacokinetics of Regorafenib
To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects
- Trial name
- NCT02001909
- Testing
- Regorafenib (Stivarga, BAY73-4506), Neomycin
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Neoplasms
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
- Trial name
- NCT01322438
- Testing
- Regorafenib (BAY73-4506) + rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Ovarian Neoplasms
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
Regorafenib is an oral multikinase inhibitor that blocks the activity of kinases involved in angiogenesis (VEGFR 1,2,3 and TEK), oncogenesis (KIT, Ret Proto-Oncogene (RET), Raf-1 Proto-Oncogene, Serine/Threonine Kinase (RAF1) and…
- Trial name
- NCT02736305
- Testing
- Regorafenib
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore